
Join to View Full Profile
Denali Therapeutics, Inc.161 Oyster Point Blvd.South San Francisco, CA 94080
Dr. Troyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Matthew Troyer is a neurologist in South San Francisco, CA. He received his medical degree from Stanford University School of Medicine and has been in practice 28 years. He specializes in movement disorder and is experienced in movement disorders, neurology, clinical research, and translational medicine.
Education & Training
- Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1993 - 1996
- Stanford University School of MedicineClass of 1992, MD
- Illinois Wesleyan UniversityBA
Clinical Trials
- Study to Evaluate DNL201 in Subjects With Parkinson's Disease Start of enrollment: 2018 Dec 04
- Study to Evaluate DNL747 in Subjects With Alzheimer's Disease Start of enrollment: 2019 Feb 13
- Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis Start of enrollment: 2018 Dec 14
- Join now to see all
Publications & Presentations
PubMed
- 39 citationsSafety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blin...Maurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld, Jerome Oude Nijhuis, Peter Paul De Deyn
Clinical and Translational Science. 2022-08-01 - 110 citationsPreclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.Danna Jennings, Sarah Huntwork-Rodriguez, Anastasia G Henry, Jennifer C Sasaki, René Meisner
Science Translational Medicine. 2022-06-08 - 36 citationsMolecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme.Annie Arguello, Cathal S Mahon, Meredith E K Calvert, Darren Chan, Jason C Dugas
The Journal of Experimental Medicine. 2022-03-07
Press Mentions
- Five Highlights from Our Conference Illustrate Momentum in Parkinson's ResearchFebruary 1st, 2020
Professional Memberships
- Member
- International Parkinson and Movement Disorder SocietyMember
Industry Relationships
- Senior Vice President, Head of Early Clinical Development, Denali Therapeutics2016 - Present
External Links
- Denali Therapeuticshttp://www.denalitherapeutics.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: